Novuson Surgical, Inc.

First substantive innovation in Advanced Energy Technology...


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

“This will change surgery forever” was the general sentiment from a University of Washington commissioned survey of applicable surgeons.

Over the last 9 years, the Novuson founders have established scientific credibility via compelling proof of concept trials. We are now transitioning from an R&D company to a manufacturing and marketing company, delivering product systems at a national then global scale.

Our technology’s performance has been solidly demonstrated, both in ex vivo tissue samples and in vivo swine trials. Now we need to invest in product development, manufacturing, and 510k FDA clearance, as well as fill out our technical and management teams with proven producers.

A highly regarded FDA consulting firm in Washington (Drug and Device Development) has issued a Position Letter indicating our FDA classification to be 510K.

We hold 5 granted US utility patents and 3 pending utility patents.  Novuson owns worldwide exclusive license to these patents.

We have received support from a number of organizations:

Madigan Military Medical Center (Joint Base Fort Lewis/McChord) invited us to join them in a Cooperative Research and Development Agreement (CRADA), in which Madigan would conduct our human subjects trials at no cost to Novuson.

National Institute of Health (NIH) has awarded us multiple grants: Phase 1 STTR grant of $225K completed with a Perfect Score. $1.5M in March of 2016 for a Direct to Phase II through NIGMS (Hemostatic Clamp), and an additional $1.5M in September of 2016 through NHLBI (Perioperative Bleeding).

Our next step is to integrate the lab prototype into a product-ready clinical system suitable for 510K clearance by the FDA. We project 6 months are needed before we launch into the US general surgical market. We will first sell our system to the top general surgery hospitals in the North American market before expanding to Europe, Japan, and China where we will use local distributing partners to enter the general surgery markets.


Stuart B Mitchell, PhD, Chairman, CEO, CSO, Inventor of the Technology, Co-Founder

Over 20 years experience in biomedical instrumentation, 10 years in acoustic device and 15 years in tissue response to stimuli. Inventor of Novuson’s technology, conceptualized the market space, and developed the business strategy. Managed million dollar corporations/projects for 30 years. Started ACCES with Jean Maixner, grew to a multi-location practice with 70% CAGR, successful exit via merger with nationwide company.

 


Jim Bazzinotti, MBA, COO, EVP Sales & Marketing

Mr. Jim Bazzinotti is a senior medical device industry executive with extensive, diversified experience in both the minimally invasive products and capital equipment sectors. A hands-on executive with broad functional bandwidth from operating room to board room. Expert in developing strategic business and marketing plans, executing both US and global product launches, creating branding campaigns, managing product life cycles and building direct sales teams and managing distributor channels. Recipient of the President’s award from both the Cordis Corporation and Elekta for outstanding performance and contributions.

 


Derek Khorsand, MD, Chief Medical Director

Dr. Khorsand will lead our clinical outreach, review Novuson's technology value proposition and provide feedback on technical usability. Dr. Khorsand is a Resident Physician of Interventional Radiology at the Univ. of WA Med Ctr. He did his Internship in General Surgery at Virginia Mason Med Ctr. Dr. Khorsand received his Doctor of Medicine from the Univ of WA School of Medicine and his Bachelor of Science in Biochemistry from the Univ of WA.

 


EVP of Operations and Finance

Dr. Maixner was the founder of Animal Critical Care and Emergency Services. She has over 25 years of emergency and critical care veterinary experience and 10 years of business management.

 


Marco Daoura, BSEE, MSBioE, SSGBC, EVP of Program and Product

With 22 years in healthcare, Marco’s work in innovation crosses multidisciplinary areas from technology, to services, program & product management, commercialization & marketing. He holds several health-tech patents, and has launched numerous successful life sciences products, where he optimizes development & commercialization strategies to improve patient outcomes, simplify provider workflows, and reduce provider/payor costs & waste.

 


Shane Cerrato, EVP of Business Development

18+ years experience in global business development, strategic marketing and sales management in the life sciences. His career has encompassed the planning and management of successful launches of niche products including: neurology, ophthalmology, cardiology and obesity products within the medical device industry. He has held progressive leadership positions and has a MBA from the University of Phoenix and a BA from Colorado State University.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.co platform

Copyright © 2017 Startups.co. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.